Antihypertensive algorithm

Phase 3Small molecule

Antihypertensive algorithm is one of 2 small molecule programs targeting Chronic Kidney Disease (CKD). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney Disease (CKD)Recruiting

Chronic Kidney Disease (CKD)Phase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Chronic Kidney Disease (CKD)

#DrugCompanyPhaseTrials

Antihypertensive algorithm

UUniversity Hospital, Tours

Phase 3

1 2

PLS240

PPathalys Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Chronic Kidney Disease (CKD)

NCT05732727

Clinical

Trials by Indication[1]

Chronic Kidney Disease (CKD)1 trial

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease: an Open Label, a Cluster Randomized Controlled, Phase 3 Trial

Recruiting·UUniversity Hospital, Tours·Phase 3·NCT05732727·720 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antihypertensive algorithm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antihypertensive algorithm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antihypertensive algorithm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Tours company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Tours

Antihypertensive algorithm

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Chronic Kidney Disease (CKD)1 trial

References

Drug Info

Quick Facts

Related News